InMode Ltd vs Synopsys, Inc. — how do they compare? InMode Ltd trades at $15.31 (market cap $882.90M), while Synopsys, Inc. trades at $381.36 (market cap $72.47B). The key difference: Synopsys, Inc. is far larger — about 82.1× InMode Ltd's market cap, and InMode Ltd is trading nearer its 52-week high, Synopsys, Inc. nearer its low. Which is the better fit depends on your goals.
| INMD | SNPS | |
|---|---|---|
Market Cap | $882.90M | $72.47B |
Sector | Technology | Technology |
52-Week High | $16.62 | $645.59 |
52-Week Low | $12.76 | $378.46 |
Enterprise Value | $350.57M | $80.82B |
Signals from Pluang's Aura AI — not financial advice
INMD trades at $15.36, down 0.71% on the day, with a bullish technical signal from moving averages but a neutral reading from oscillators. The company maintains strong profitability with a 77.84% gross margin and 23.27% net margin, though Q1 2026 earnings missed expectations. Recent news includes an unsolicited acquisition offer of $16.75 per share from Steel Partners and upcoming Q2 2026 results on August 5, 2026.
The stock presents a mixed outlook: attractive valuation multiples and a solid balance sheet support upside, but risks include earnings volatility, shareholder activism, and a securities fraud investigation. Analyst consensus is a $16.50 price target with a balanced buy/hold rating split, suggesting cautious optimism near-term.
Synopsys (SNPS) trades at $378.47, down 1.51% amid a semiconductor sector downturn. The stock shows bearish technical signals but maintains strong fundamentals with consistent earnings beats and a high analyst buy consensus of 82.76%. Recent news highlights the company's strategic pivot to AI design tools and margin expansion following the Ansys integration.
Outlook remains positive long-term due to SNPS's critical role in AI chip design, though near-term risks include sector volatility and execution of high-margin transitions. The consensus price target of $559.50 implies significant upside, but investors should monitor competitive pressures and macroeconomic headwinds.
Trailing returns across standard periods
InMode provides innovative medical technologies for minimally invasive surgical procedures. Its platforms use radiofrequency (RF) energy for aesthetic treatments like body contouring and skin tightening.
Read more on INMD →Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →